Adicet Bio shareholders approve directors and auditor

Adicet Bio, Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026, where three governance proposals were presented for vote.

Rhea-AI Filing Summary

Adicet Bio, Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026, where three governance proposals were presented for vote. Stockholders elected Class II directors Jeffrey Chodakewitz, Steve Dubin and Michael Grissinger to three-year terms ending at the 2029 annual meeting.

Support was strong for all three nominees, with votes for ranging from 4,596,116 to 5,257,041 and broker non-votes of 1,384,153. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 4,611,540 votes for and 745,537 against.

In addition, stockholders ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 6,719,352 votes for and 25,206 against. No other matters were submitted to a vote at the meeting.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for Chodakewitz: 4,629,969 votes Votes for Dubin: 4,596,116 votes Votes for Grissinger: 5,257,041 votes +4 more

7 metrics

Votes for Chodakewitz 4,629,969 votes Election as Class II director at 2026 annual meeting

Votes for Dubin 4,596,116 votes Election as Class II director at 2026 annual meeting

Votes for Grissinger 5,257,041 votes Election as Class II director at 2026 annual meeting

Say-on-pay votes for 4,611,540 votes Non-binding advisory approval of executive compensation

Say-on-pay votes against 745,537 votes Non-binding advisory approval of executive compensation

Auditor ratification votes for 6,719,352 votes Ratification of KPMG LLP for fiscal year ending December 31, 2026

Auditor ratification votes against 25,206 votes Ratification of KPMG LLP for fiscal year ending December 31, 2026

Key Terms

Annual Meeting of Stockholders, Class II directors, non-binding advisory basis, independent registered public accounting firm, +1 more

5 terms

Annual Meeting of Stockholders regulatory

"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."

Class II directors financial

"elected Jeffrey Chodakewitz, Steve Dubin and Michael Grissinger as Class II directors"

non-binding advisory basis regulatory

"approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers."

A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.

independent registered public accounting firm financial

"ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

broker non-votes financial

"Votes For | | Votes Withheld | | Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Adicet Bio (ACET) stockholders vote on at the 2026 annual meeting?

Stockholders voted on three proposals: election of three Class II directors, a non-binding advisory vote on executive compensation, and ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Who was elected to Adicet Bio’s (ACET) board as Class II directors in 2026?

Jeffrey Chodakewitz, Steve Dubin and Michael Grissinger were elected as Class II directors. Each will serve a three-year term ending at the 2029 annual meeting and continue until a successor is duly elected and qualified or earlier resignation or removal.

How did Adicet Bio (ACET) stockholders vote on executive compensation in 2026?

Stockholders approved, on a non-binding advisory basis, the compensation of Adicet Bio’s named executive officers. The vote totaled 4,611,540 shares for, 745,537 against, 4,939 abstentions and 1,384,153 broker non-votes, indicating overall support for the company’s compensation practices.

Was KPMG LLP ratified as Adicet Bio’s (ACET) auditor for 2026?

Yes. Stockholders ratified the selection of KPMG LLP as Adicet Bio’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 6,719,352 votes for, 25,206 against and 1,611 abstentions reported in the voting results.

What were the vote totals for Adicet Bio (ACET) director nominee Michael Grissinger?

For director nominee Michael Grissinger, stockholders cast 5,257,041 votes for and 104,975 votes withheld, with 1,384,153 broker non-votes. This result confirmed his election as a Class II director to serve until the 2029 annual meeting of stockholders.

Were there any other matters voted on at Adicet Bio’s (ACET) 2026 annual meeting?

No. The company reported that no other matters were submitted to or voted on by stockholders at the 2026 Annual Meeting beyond director elections, the advisory vote on executive compensation, and ratification of the independent registered public accounting firm.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:01 PM EDT Learn about SEC filing dates

false000172058000017205802026-06-172026-06-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2026

Adicet Bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38359	81-3305277
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
131 Dartmouth Street, Floor 3
Boston, Massachusetts				02116
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 503-9095

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ACET		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 17, 2026, Adicet Bio, Inc., a Delaware corporation (the “Company”), held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the three proposals set forth below, each of which is described in greater detail in the Company’s definitive proxy statement on Schedule 14A, which was filed with the U.S. Securities and Exchange Commission on April 29, 2026. The final voting results are set forth below.

Proposal 1 – Election of Class II Director Nominees

The stockholders of the Company elected Jeffrey Chodakewitz, Steve Dubin and Michael Grissinger as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until their successors have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class II directors were as follows:

Name		Votes For		Votes Withheld		Broker Non-Votes
Jeffrey Chodakewitz		4,629,969		732,047		1,384,153
Steve Dubin		4,596,116		765,900		1,384,153
Michael Grissinger		5,257,041		104,975		1,384,153

Proposal 2 – Non-Binding Advisory Vote on Compensation of the Company’s Named Executive Officers

The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The results of the stockholders’ vote with respect to the compensation of the Company’s named executive officers were as follows:

Votes For		Votes Against		Abstain		Broker Non-Votes
4,611,540		745,537		4,939		1,384,153

Proposal 3 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm

The stockholders of the Company ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows:

Votes For		Votes Against		Abstain		Broker Non-Votes
6,719,352		25,206		1,611		N/A

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ADICET BIO, INC.
Date: June 18, 2026		By:	/s/ Nick Harvey
		Name:	Nick Harvey
		Title:	Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.6 KB